Seeing Colchicine in a New Light: Repurposing Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

This review presents a modern perspective on the cardiovascular re-purposing of colchicine, the oldest drug in the pharmacopeia other than aspirin that is still in regular use. This article presents a brief overview of colchicine's long history as a medicine, as well as a critical review of saf...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2023-11, Vol.45 (11), p.1029-1033
Main Author: Nidorf, Stefan Mark
Format: Article
Language:English
Subjects:
Anti-inflammatory agents
Anti-Inflammatory Agents - therapeutic use
Antifungal agents
Arteriosclerosis
Aspirin
Atherosclerosis
Atherosclerosis - drug therapy
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - complications
Cardiovascular Diseases - prevention & control
Clinical trials
Colchicine
Colchicine - adverse effects
Coronary Artery Disease - drug therapy
Disease prevention
Drug dosages
Drug overdose
Drug Repositioning
Familial Mediterranean fever
Gout
Gout - drug therapy
Heart attacks
Heart diseases
Humans
Inflammation
Leukocytes
Lipids
Liver diseases
Low-dose colchicine
Neutrophils
Prevention
Rheumatism
Safety
Secondary prevention
Secondary Prevention - methods
Symptom Flare Up
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review presents a modern perspective on the cardiovascular re-purposing of colchicine, the oldest drug in the pharmacopeia other than aspirin that is still in regular use. This article presents a brief overview of colchicine's long history as a medicine, as well as a critical review of safety and efficacy from the results of recent cardiovascular clinical trials. Long-term continuous colchicine use at doses between 0.6 and 2.4 mg has been used to prevent inflammatory flares in patients with gout and familial Mediterranean fever and less commonly employed in a range of other inflammatory conditions. In these settings, lifelong therapy has been found to be safe and well tolerated. Understanding the central role of inflammation in atherosclerosis has led to the search for effective anti-inflammatory agents that can be used continuously in combination with a range of other medications, including lipid-lowering therapies, antiplatelet therapy, and anticoagulants. The results of recent robust randomized clinical trials of low-dose colchicine (0.5 mg daily) in patients with coronary disease recently led the US Food and Drug Administration to approve its use as a new cornerstone therapy for secondary prevention in patients with coronary disease. Several misconceptions regarding the safety and tolerability of low dose colchicine are addressed. Colchicine has emerged from its traditional role in medicine as the prevention of gout flare as the first anti-inflammatory agent to be approved by the US Food and Drug Administration for the secondary prevention of atherosclerosis.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2023.07.007